Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 28.0% during the first quarter of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first quarter the biotech indices averaged a 15.2% gain.
Immunocellular Therapeutics (43%), Advaxis (197%) and Celldex (73%) have led the sector in gains during the January thru March 2013 period. Dendreon ($731 Million), Celldex ($718 Million) and Vical ($343 Million) represent 62% of the market capitalization of the fifteen member Cancer Immunotherapy Index which has a combined total share value of $2.9 Billion.
The Mentor Capital Cancer Immunotherapy Index companies and their performance for the first thirteen weeks of 2013 follow: Galena Biopharma Corporation +37.25%, NewLink Genetics Corporation -1.84%, Vical Incorporated +36.77%, Inovio Pharmaceuticals, Inc. +19.12%, Dendreon (NASDAQ:DNDN) -10.49%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +42.71%, Agenus (NASDAQ:AGEN) -5.12%, Oncothyreon (NASDAQ:ONTY) +8.07%, Biovest International (Pink Sheets:BVTIQ) -8.80%, Celldex Therapeutics (NASDAQ:CLDX) +72.58%, Northwest Biotherapeutics (NASDAQ:NWBO) +18.60%, CEL – SCI Corp. (NYSE MKT:CVM) -14.44% , Generex Biotechnology (OTCBB:GNBT) +24.00% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (Pink Sheets:PVCT) +30.36% and Advaxis, Inc. (OTCBB:ADXS) +196.67% - all for an average 2013 YTD gain of +27.97%. (Annualized rate: 112.20%).
Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies, and certain other situations. Mentor created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index which can be found at www.MentorCapital.com .
Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.
For further information contact:
Chester Billingsley, CEO
Mentor Capital, Inc.
(760) 788 - 4700
